CareFusion Bid Lower on Q4 Earnings Results

Shares of CareFusion CFN are trading lower in the after-hours following the release of the company's Q2 earnings results. Currently, shares are bid $20.00, at $22.26; they ended the regular session lower by 7.33%, at $22.26. CareFusion reported Q4 Adjusted EPS of $0.52 on revenues of $964 million. For the fiscal year ending June 30, 2012, CareFusion expects revenues to grow 3 to 5 percent on a constant currency basis compared to fiscal 2011 revenue of $3.53 billion. Adjusted diluted earnings per share for fiscal 2012 are expected to be in the range of $1.80 to $1.90. "Growth in our Infusion, Dispensing and Infection Prevention businesses, gross margin expansion and the benefit of strong spending controls drove double digit improvements in our adjusted operating earnings for the quarter and for the year," said Kieran Gallahue, chairman and CEO. "We continue to make progress in optimizing our product portfolio and expanding our geographical footprint. We recently acquired pharmacy automation innovator Rowa, enabling us to expand our Pyxis platform outside the U.S." CareFusion Corporation is a global medical technology company. The company offers product lines in the areas of IV infusion, medication and supply dispensing, respiratory care, infection prevention and surgical instruments.